Jump to content
  • Sign Up
Celiac.com Sponsor:

Celiac.com Sponsor:

  • Join Our Community!

    Get help in our celiac / gluten-free forum.

  • Jefferson Adams

    What's Up with the Cystic Fibrosis Transmembrane Conductance Regulator in Celiac Disease?

    Jefferson Adams

    Reviewed and edited by a celiac disease expert.

      New results show that the cystic fibrosis transmembrane conductance regulator plays an early and crucial role in guiding gliadin activities, and reveal a new therapeutic possibility for treating celiac disease.

    Caption: Image: CC BY 2.0--eflon

    Celiac.com 08/15/2019 - Does the cystic fibrosis transmembrane conductance regulator play a pathogenic role in celiac disease?

    Usually, when people consume dietary proteins, their guts prevent local inflammatory and immune responses, and encourage oral tolerance to the proteins. However, for about one out of a hundred people worldwide, gluten and related cereals trigger an HLA DQ2/8-restricted TH immune and antibody response, which develops into celiac disease, if untreated. 

    Celiac.com Sponsor:

    Prior epithelial stress and innate immune activation are required to break oral tolerance to gliadin. How gliadin subverts host intestinal mucosal defenses remains elusive. Does the cystic fibrosis transmembrane conductance regulator play a pathogenic role in celiac disease?

    A team of researchers recently set out to shed some light on the way gliadin subverts host intestinal mucosal defenses. The research team included Valeria R Villella, Andrea Venerando, Giorgio Cozza, Speranza Esposito, Eleonora Ferrari, Romina Monzani, Mara C Spinella, Vasilis Oikonomou, Giorgia Renga, Antonella Tosco, Federica Rossin, Stefano Guido, Marco Silano, Enrico Garaci, Yu-Kai Chao , Christian Grimm, Alessandro Luciani, Luigina Romani, Mauro Piacentini, Valeria Raia, Guido Kroemer & Luigi Maiuri.

    Their team demonstrated that the a-gliadin-derived LGQQQPFPPQQPY peptide (P3–43) inhibits the function of cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel pivotal for epithelial adaptation to cell-autonomous or environmental stress. 

    P3–43 binds to, and reduces ATPase activity of, the nucleotide-binding domain- (NBD) of CFTR, thus impairing CFTR function. This creates epithelial stress, tissue transglutaminase and inflammasome activation, NF-jB nuclear translocation and IL-5 production, that all can be prevented by potentiators of CFTR channel gating. 

    The CFTR potentiator VX-770 reduces gliadin-induced inflammation and promotes tolerance in gluten-sensitive mice and cells from patients with celiac disease. 

    The team's results show that CFTR plays an early and crucial role in guiding gliadin activities, and reveals a new therapeutic possibility for treating celiac disease.

    Stay tuned for more developments on this and related stories.

    Read more at the EMBO Journal (209) 38: e000


    The researchers are variously affiliated with the European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy; the Department of Comparative Biomedicine and Food Science, University of Padova, Padova, Italy; the Department of Molecular Medicine, University of Padova, Padova, Italy; the Department of Health Sciences, University of Eastern Piedmont, Novara, Italy; the Department of Experimental Medicine, University of Perugia, Perugia, Italy; the Pediatric Unit, Department of Translational Medical Sciences, Regional Cystic Fibrosis Center, Federico II University Naples, Naples, Italy; the Department of Biology, University of Rome “Tor Vergata”, Rome, Italy; Department of Chemical, Materials and Production Engineering, Federico II University Naples, Naples, Italy; the Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Roma, Italy; University San Raffaele and 21 IRCCS San Raffaele, Rome, Italy; Department of Pharmacology and Toxicology, Faculty of Medicine, University of Munich (LMU), Munich, Germany; the Institute of Physiology CH, University of Zurich, Zurich, Switzerland; the National Institute for Infectious Diseases IRCCS “L. Spallanzani”, Rome, Italy; the Centre de Recherche des Cordeliers, Equipe11 labellisée Ligue Nationale Contrele Cancer, Paris, France; the Centre de Recherche des Cordeliers, INSERM U1138, Paris, France; the Université Paris Descartes, Paris, France; the Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France; the Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; and the Department of Women’s and Children’s Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

    User Feedback

    Recommended Comments

    There are no comments to display.

    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Add a comment...

    ×   Pasted as rich text.   Paste as plain text instead

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.

  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.

  • Related Articles

    Jefferson Adams
    Celiac.com 12/21/2015 - For people with celiac disease, gluten immunogenic peptides might reveal whether you've been bad or good on your gluten-free diet, and whether or not you have gut damage.
    In fact, the best way to spot transgressions in the gluten-free diet and incomplete mucosal healing in people with celiac disease might just be to check for gluten immunogenic peptides...

    Jefferson Adams
    Celiac.com 12/31/2018 - Rates of celiac disease are about triple for patients who also suffer from cystic fibrosis, compared to those without cystic fibrosis. A team of researchers recently investigated the molecular similarities between celiac disease and cystic fibrosis. Specifically, they set out to examine the role of mutations of the gene coding for cystic fibrosis transmembrane ...

  • Celiac.com Sponsor:

  • Forum Discussions

    Personallyu Well, actually there are plenty of studies showing the ingredients in GliadinX in fact does break down gluten by 50-85% before it reaches the small intestine. I believe the reason Scott recommends using it when you are ...
    I’ve been gluten free going on 14 years and as you all know accidents happen along the way especially when you are eating at someone else’s house or restaurants. ive been getting these attacks throughout the years and after having another one ...
    Have your doctors check for Mast Cell Activation Syndrome, which is still pretty new and not well known (not an IgE response, but similar in terms of symptoms).    It can be extreme or mild.   My triggers are insect bites and medications lik...
  • Create New...